“Pfizer” .. a booster dose of the vaccine is effective against the Corona virus and its variants

Dubai, United Arab Emirates (CNN) – The companies “Pfizer” and “BioNTech” announced Monday that they have submitted preliminary data to the US Food and Drug Administration, to support the use of a booster dose of the vaccine “Covid- 19 “.

The booster dose elicited a significantly higher antibody response against the primary strain of MERS-CoV, as well as the delta and beta variants, compared to what was seen in subjects who received both doses.

The booster dose appears to be protective against the “delta” and “beta” variants to the same extent to protect it from the original coronavirus.

Given the high levels of immune responses seen, providing a booster dose within 6 to 12 months of the baseline immunization schedule may help maintain a high level of protection against COVID-19, a statement said.

“The booster vaccine can help reduce infection and disease rates in people previously vaccinated and better control the spread of viral variants over the next season,” said Dr Ugur Sahin, CEO and co- founder of BioNTech.

The booster dose data comes as COVID-19 cases and hospitalizations have increased in recent weeks, especially among unvaccinated people in the south.

Pfizer executives believe a booster will be needed soon, but health officials in the United States have said they have yet to see any indication that it is needed.

Health officials have focused on persuading unvaccinated people to receive the vaccine. As of Monday, 50.7% of the entire U.S. population had been vaccinated, according to data from the Centers for Disease Control and Prevention.